Double maintains 1 strategies that include SAVA - Cassava Sciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MTD | -<0.01% | $24.10B | -12.47% | 0.00% |
RNR | -0.01% | $12.01B | +6.07% | 0.65% |
HAS | 0.01% | $8.67B | +11.46% | 4.56% |
STC | 0.01% | $2.01B | +13.31% | 2.78% |
CHGG | -0.01% | $64.89M | -91.34% | 0.00% |
IIPR | 0.01% | $1.58B | -43.78% | 13.71% |
R | 0.01% | $6.11B | +23.92% | 2.18% |
KT | -0.01% | $8.70B | +30.46% | 2.05% |
OCX | -0.02% | $85.80M | +2.39% | 0.00% |
NOC | -0.03% | $74.27B | +10.02% | 1.61% |
FBRT | -0.03% | $1.05B | -0.93% | 11.28% |
BXSL | 0.03% | - | - | 9.45% |
BRKR | -0.04% | $6.13B | -55.58% | 0.50% |
PNFP | 0.04% | $8.10B | +27.81% | 0.87% |
BTSG | 0.04% | $3.14B | +69.73% | 0.00% |
VICI | 0.04% | $34.28B | +10.08% | 5.29% |
GGG | 0.05% | $14.19B | -8.12% | 1.24% |
CPRX | -0.05% | $2.91B | +56.75% | 0.00% |
OXBR | 0.05% | $14.38M | +70.98% | 0.00% |
CSL | -0.05% | $15.15B | -12.27% | 1.12% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PZA | 0.01% | $2.97B | 0.28% |
RSPD | -0.01% | $200.13M | 0.4% |
XHB | -0.02% | $1.37B | 0.35% |
GBIL | 0.04% | $6.31B | 0.12% |
USCI | -0.05% | $237.61M | 1.07% |
HYBL | -0.05% | $344.11M | 0.7% |
VTEB | 0.05% | $35.87B | 0.03% |
DIAL | -0.06% | $355.41M | 0.29% |
IAGG | -0.07% | $6.72B | 0.07% |
IYT | -0.08% | $588.86M | 0.39% |
SRLN | -0.08% | $7.75B | 0.7% |
RWO | 0.09% | $1.09B | 0.5% |
ISRA | -0.10% | $90.40M | 0.59% |
IBMP | -0.10% | $513.83M | 0.18% |
CGSD | -0.10% | $1.09B | 0.25% |
UBND | 0.11% | $627.77M | 0.4% |
FMB | -0.14% | $2.00B | 0.65% |
FHLC | 0.14% | $2.70B | 0.084% |
GTO | -0.14% | $1.89B | 0.35% |
DIV | 0.15% | $654.90M | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLTR | -18.58% | $2.42B | 0.14% |
FLRN | -16.49% | $2.82B | 0.15% |
VRIG | -15.24% | $1.44B | 0.3% |
JBBB | -14.72% | $1.74B | 0.49% |
EZET | -14.70% | $21.63M | 0% |
ETHW | -14.40% | $174.65M | 0% |
QETH | -14.38% | $13.73M | 0.25% |
FETH | -14.30% | $733.92M | 0.25% |
CETH | -14.28% | $8.44M | 0% |
ETHA | -14.15% | $2.19B | 0.25% |
ETHV | -14.13% | $84.73M | 0% |
BTC | -13.95% | $3.28B | 0.15% |
ETH | -13.14% | $1.29B | 0% |
BILZ | -12.59% | $691.33M | 0.14% |
CSHI | -11.12% | $529.22M | 0.38% |
THTA | -10.85% | $51.60M | 0.49% |
HYEM | -9.52% | $408.26M | 0.4% |
PULS | -8.90% | $11.02B | 0.15% |
SEIX | -8.60% | $331.99M | 0.57% |
BTAL | -8.22% | $414.68M | 1.43% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XPH | 25.72% | $164.53M | 0.35% |
CPSJ | 20.56% | $32.86M | 0.69% |
PHDG | 18.90% | $114.58M | 0.39% |
PTH | 18.42% | $111.59M | 0.6% |
NUKZ | 18.30% | $184.96M | 0.85% |
URA | 17.72% | $2.62B | 0.69% |
URNM | 17.54% | $1.22B | 0.75% |
AMDY | 16.21% | $144.02M | 1.23% |
YLD | 16.05% | $301.42M | 0.39% |
URNJ | 16.03% | $202.37M | 0.8% |
WTMF | 15.93% | $156.99M | 0.65% |
HIGH | 15.85% | $196.63M | 0.52% |
TESL | 15.80% | $15.83M | 1.2% |
SMH | 15.32% | $19.14B | 0.35% |
SOXQ | 15.19% | $383.31M | 0.19% |
SOXX | 15.15% | $10.82B | 0.35% |
SGOL | 15.08% | $4.81B | 0.17% |
OUNZ | 15.06% | $1.49B | 0.25% |
AAAU | 15.02% | $1.29B | 0.18% |
FTXL | 14.83% | $234.63M | 0.6% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SEG | -22.17% | $265.11M | -18.92% | 0.00% |
BBWI | -22.15% | $6.56B | -36.52% | 2.64% |
GLNG | -19.67% | $3.88B | +51.35% | 2.75% |
OPI | -19.38% | $31.58M | -76.56% | 8.84% |
IRTC | -18.36% | $3.36B | -2.17% | 0.00% |
KODK | -18.30% | $498.91M | +27.89% | 0.00% |
QUAD | -17.31% | $289.48M | +5.53% | 4.10% |
VZ | -17.00% | $191.04B | +6.68% | 5.93% |
FIZZ | -15.66% | $3.96B | -8.65% | 0.00% |
CNP | -15.55% | $23.98B | +29.40% | 2.25% |
BG | -15.46% | $10.43B | -25.07% | 3.50% |
INGR | -14.18% | $8.73B | +16.81% | 2.35% |
HRL | -13.40% | $16.90B | -12.77% | 3.70% |
HRZN | -12.84% | - | - | 13.94% |
HTGC | -12.58% | - | - | 8.87% |
CGBD | -12.54% | - | - | 9.93% |
LIF | -12.50% | $2.90B | +42.15% | 0.00% |
NGL | -12.41% | $615.18M | -19.38% | 0.00% |
VUZI | -12.22% | $147.91M | +53.97% | 0.00% |
CBZ | -12.17% | $4.14B | +0.63% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SUNS | 20.95% | $146.29M | -3.54% | 8.38% |
WBX | 20.50% | $85.30M | -77.60% | 0.00% |
MLI | 19.92% | $8.78B | +48.36% | 1.11% |
MVIS | 19.37% | $291.56M | -29.59% | 0.00% |
BX | 19.12% | $174.02B | +13.06% | 2.81% |
RARE | 18.25% | $3.13B | -27.37% | 0.00% |
RMBL | 18.20% | $101.65M | -56.68% | 0.00% |
AVXL | 18.19% | $682.21M | +76.65% | 0.00% |
FDMT | 18.02% | $138.44M | -89.31% | 0.00% |
DASH | 18.00% | $76.63B | +32.67% | 0.00% |
DNLI | 18.00% | $1.78B | -36.58% | 0.00% |
VRT | 17.87% | $28.66B | -6.81% | 0.17% |
MOD | 17.68% | $4.22B | -13.93% | 0.00% |
NKE | 17.64% | $95.79B | -28.80% | 2.40% |
MSI | 17.56% | $72.78B | +23.84% | 0.95% |
STRL | 17.47% | $3.54B | +9.64% | 0.00% |
GEV | 17.38% | $87.09B | +125.46% | 0.00% |
DESP | 17.30% | $1.57B | +57.01% | 0.00% |
CRMD | 17.19% | $395.65M | +48.77% | 0.00% |
CRBU | 17.04% | $78.23M | -82.40% | 0.00% |
Yahoo
The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
Yahoo
NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam. U.S. District Judge Jennifer Rochon in Manhattan said Adrian Heilbut, Jesse Brodkin, Enea Milioris, David Bredt and Geoffrey Pitt could try to prove that Cassava knew or should have known that it could not win its defamation lawsuit against them, which it dismissed in August.
Yahoo
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
Yahoo
While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.
Yahoo
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Current Value
$1.491 Year Return
Current Value
$1.491 Year Return